Table 4.
Predictors of death-censored graft failure for a median 4.5 years of follow-up: univariable analysis
| HR | SE | P-value | LCL | UCL | |
|---|---|---|---|---|---|
| Urine markers | |||||
| Log UPodCR | 2.26 | 0.65 | 0.004 | 1.29 | 3.97 |
| Log UNephCR | 1.88 | 0.66 | 0.07 | 0.95 | 3.76 |
| Log UAqp2CR | 0.81 | 0.27 | 0.53 | 0.43 | 1.55 |
| Log UTGFβ1CR | 1.31 | 0.23 | 0.13 | 0.93 | 1.85 |
| Log UProtCR | 1.90 | 0.55 | 0.03 | 1.08 | 3.35 |
| Recipient | |||||
| Age | 1.00 | 0.02 | 0.99 | 0.96 | 1.05 |
| Black race | 4.56 | 3.06 | 0.02 | 1.22 | 17.0 |
| Gender, male | 0.65 | 0.43 | 0.52 | 0.17 | 2.41 |
| BSA | 2.89 | 3.61 | 0.39 | 0.25 | 33.3 |
| cPRA | 1.01 | 0.01 | 0.11 | 0.99 | 1.03 |
| Dialysis vintage (ref: no dialysis or <2 years) | |||||
| Dialysis >2 years | 2.28 | 0.68 | 0.006 | 1.27 | 4.10 |
| Previous transplant | 4.47 | 3.63 | 0.07 | 0.91 | 22.0 |
| Donor | |||||
| Age | 1.01 | 0.03 | 0.61 | 0.96 | 1.07 |
| Black race | 4.20 | 2.98 | 0.04 | 1.05 | 16.9 |
| Male sex | 1.22 | 0.82 | 0.77 | 0.33 | 4.53 |
| BSA | 0.29 | 0.33 | 0.28 | 0.03 | 2.74 |
| Transplant | |||||
| Cadaveric transplant | 2.66 | 1.79 | 0.14 | 0.71 | 9.95 |
| Cold ischemia time | 1.08 | 0.04 | 0.03 | 1.00 | 1.15 |
| HLA mismatch | |||||
| 3–4 | 0.15 | 0.17 | 0.1 | 0.02 | 140 |
| 5–6 | 0.79 | 0.56 | 0.74 | 0.20 | 3.19 |
| First year | |||||
| DSA in first year | 1.86 | 1.50 | 0.44 | 0.39 | 9.02 |
| Rejection in first year | 0.84 | 0.58 | 0.80 | 0.22 | 3.23 |
| 1-year serum creatinine | 3.81 | 2.05 | 0.01 | 1.33 | 10.96 |
| First-year biopsies | |||||
| (ref: GGS <10%) | |||||
| GGS >10% | 5.39 | 3.63 | 0.01 | 1.44 | 20.2 |
| Recurrent or de novo GD | 13.0 | 8.80 | 0.0001 | 3.47 | 49.0 |
| IFTA (ref: No IFTA) | |||||
| Mild | 1.21 | 1.06 | 0.82 | 0.22 | 6.70 |
| Moderate–severe | 3.10 | 2.84 | 0.22 | 0.52 | 18.7 |
Due to nonconvergence of the model, preemptive and dialysis time <2 years were combined into one group. Given that only 10 graft losses (events) occurred in the absence of death, we did not perform multivariable analysis. Cause of ESRD was not shown in the tables due to the nonconvergence of models. IFTA was defined as mild (<25%), moderate (25–50%) and severe (>50% of the total area).
UNephCR, urine nephrin mRNA:creatinine ratio, UAqp2CR, urine aquaporin 2 mRNA:urine creatinine ratio; UTGFβ1CR, urine transforming growth factor β mRNA:urine creatinine ratio; UProtCR, urine protein:urine creatinine ratio; AA, African American; cPRA, calculated panel reactive antibody; HLA, human leukocyte antigen; DSA, donor-specific antibody; GGS, global glomerulosclerosis; LCL, lower confidence limit; UCL, upper confidence limit.